For the year ending 2025-12-31, EMMA had $738K increase in cash & cash equivalents over the period. -$12K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -7,492 |
| Depreciation and amortization | 39 |
| Inventory reserve | -111 |
| Amortization of discount of notes payable and convertible notes payable | 560 |
| Foreign exchange adjustments | 38 |
| Realized loss on investment in convertible bond | -531 |
| Loss on debt extinguishment | -1,363 |
| (gain) loss on leased assets | 861 |
| Share-based compensation | 25 |
| Change in fair value of warrant derivative liabilities | -5 |
| Change in fair value of conversion feature derivative, notes payable | 162 |
| Accounts receivable | 182 |
| Inventories | 21 |
| Prepaid expenses and other current assets | 140 |
| Other non-current assets | -323 |
| Accounts payable and accrued expenses | 6,456 |
| Other liabilities | -184 |
| Operating lease liabilities | -344 |
| Net cash flows used in operating activities | -11 |
| Proceeds from sale of convertible bond | 2,172 |
| Purchases of property and equipment | 1 |
| Net cash flows provided by investing activities | 2,171 |
| Proceeds from notes payable issued | 7,908 |
| Payments of notes payable | 8,883 |
| Payments of notes payable, related party | 240 |
| Payments of convertible notes | 210 |
| Net cash flows used in financing activities | -1,425 |
| Effect of exchange rate changes on cash | 3 |
| Net increase (decrease) in cash and cash equivalents | 738 |
| Cash and cash equivalents, beginning of year | 1,389 |
| Cash and cash equivalents, end of year | 2,127 |
Emmaus Life Sciences, Inc. (EMMA)
Emmaus Life Sciences, Inc. (EMMA)